Review





Similar Products

jnj 7706621  (MedChemExpress)
93
MedChemExpress jnj 7706621
( A ) Workflow diagram illustrating the process of obtaining thermogenic gene expression profiles associated with browning promotion from RNA-seq data in the GEO database, followed by the use of the CMap database to screen for small molecule compounds that promote browning. ( B ) Heatmap of the top 100 upregulated genes from four RNA-seq datasets. The remaining 100 genes are listed in Table . ( C ) Venn diagram of the four small molecule compound sets identified. ( D ) Representative immunoblot of Ucp1 protein in primary inguinal adipocytes treated with ten candidate small molecule compounds. Rosiglitazone is used as a positive control for adipose browning promotion. ( E ) Relative mRNA expression levels of Ucp1 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9610; Control vs. AT-7519, p = 0.0015; Control vs. BMS-345541, p = 0.9888; Control vs. CGP-60474, p = 0.9994; Control vs. ER-27319, p < 0.0001; Control vs. <t>JNJ-7706621,</t> p < 0.0001; Control vs. Alvocidib, p = 0.0170; Control vs. Daunorubicin, p = 0.0004; Control vs. Isomerazin, p < 0.0001; Control vs. Pirarubicin, p < 0.0001. ( F ) Relative mRNA expression levels of Fabp4 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9974; Control vs. AT-7519, p = 0.0017; Control vs. BMS-345541, p = 0.9975; Control vs. CGP-60474, p = 0.0002; Control vs. ER-27319, p = 0.0005; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0032; Control vs. Daunorubicin, p < 0.0001; Control vs. Isomerazin, p = 0.9995; Control vs. Pirarubicin, p < 0.0001. n presents biological replicates. Data are presented as mean ± SEM. Statistical test: one-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical significance is indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns indicates no significant difference. .
Jnj 7706621, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jnj 7706621/product/MedChemExpress
Average 93 stars, based on 1 article reviews
jnj 7706621 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
jnj-7706621  (Selleck Chemicals)
90
Selleck Chemicals jnj-7706621
( A ) Workflow diagram illustrating the process of obtaining thermogenic gene expression profiles associated with browning promotion from RNA-seq data in the GEO database, followed by the use of the CMap database to screen for small molecule compounds that promote browning. ( B ) Heatmap of the top 100 upregulated genes from four RNA-seq datasets. The remaining 100 genes are listed in Table . ( C ) Venn diagram of the four small molecule compound sets identified. ( D ) Representative immunoblot of Ucp1 protein in primary inguinal adipocytes treated with ten candidate small molecule compounds. Rosiglitazone is used as a positive control for adipose browning promotion. ( E ) Relative mRNA expression levels of Ucp1 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9610; Control vs. AT-7519, p = 0.0015; Control vs. BMS-345541, p = 0.9888; Control vs. CGP-60474, p = 0.9994; Control vs. ER-27319, p < 0.0001; Control vs. <t>JNJ-7706621,</t> p < 0.0001; Control vs. Alvocidib, p = 0.0170; Control vs. Daunorubicin, p = 0.0004; Control vs. Isomerazin, p < 0.0001; Control vs. Pirarubicin, p < 0.0001. ( F ) Relative mRNA expression levels of Fabp4 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9974; Control vs. AT-7519, p = 0.0017; Control vs. BMS-345541, p = 0.9975; Control vs. CGP-60474, p = 0.0002; Control vs. ER-27319, p = 0.0005; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0032; Control vs. Daunorubicin, p < 0.0001; Control vs. Isomerazin, p = 0.9995; Control vs. Pirarubicin, p < 0.0001. n presents biological replicates. Data are presented as mean ± SEM. Statistical test: one-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical significance is indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns indicates no significant difference. .
Jnj 7706621, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jnj-7706621/product/Selleck Chemicals
Average 90 stars, based on 1 article reviews
jnj-7706621 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
jnj 7706621 catalog number hy 10329  (MedChemExpress)
93
MedChemExpress jnj 7706621 catalog number hy 10329
( A ) Workflow diagram illustrating the process of obtaining thermogenic gene expression profiles associated with browning promotion from RNA-seq data in the GEO database, followed by the use of the CMap database to screen for small molecule compounds that promote browning. ( B ) Heatmap of the top 100 upregulated genes from four RNA-seq datasets. The remaining 100 genes are listed in Table . ( C ) Venn diagram of the four small molecule compound sets identified. ( D ) Representative immunoblot of Ucp1 protein in primary inguinal adipocytes treated with ten candidate small molecule compounds. Rosiglitazone is used as a positive control for adipose browning promotion. ( E ) Relative mRNA expression levels of Ucp1 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9610; Control vs. AT-7519, p = 0.0015; Control vs. BMS-345541, p = 0.9888; Control vs. CGP-60474, p = 0.9994; Control vs. ER-27319, p < 0.0001; Control vs. <t>JNJ-7706621,</t> p < 0.0001; Control vs. Alvocidib, p = 0.0170; Control vs. Daunorubicin, p = 0.0004; Control vs. Isomerazin, p < 0.0001; Control vs. Pirarubicin, p < 0.0001. ( F ) Relative mRNA expression levels of Fabp4 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9974; Control vs. AT-7519, p = 0.0017; Control vs. BMS-345541, p = 0.9975; Control vs. CGP-60474, p = 0.0002; Control vs. ER-27319, p = 0.0005; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0032; Control vs. Daunorubicin, p < 0.0001; Control vs. Isomerazin, p = 0.9995; Control vs. Pirarubicin, p < 0.0001. n presents biological replicates. Data are presented as mean ± SEM. Statistical test: one-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical significance is indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns indicates no significant difference. .
Jnj 7706621 Catalog Number Hy 10329, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jnj 7706621 catalog number hy 10329/product/MedChemExpress
Average 93 stars, based on 1 article reviews
jnj 7706621 catalog number hy 10329 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
tr0686105  (MedChemExpress)
93
MedChemExpress tr0686105
( A ) Workflow diagram illustrating the process of obtaining thermogenic gene expression profiles associated with browning promotion from RNA-seq data in the GEO database, followed by the use of the CMap database to screen for small molecule compounds that promote browning. ( B ) Heatmap of the top 100 upregulated genes from four RNA-seq datasets. The remaining 100 genes are listed in Table . ( C ) Venn diagram of the four small molecule compound sets identified. ( D ) Representative immunoblot of Ucp1 protein in primary inguinal adipocytes treated with ten candidate small molecule compounds. Rosiglitazone is used as a positive control for adipose browning promotion. ( E ) Relative mRNA expression levels of Ucp1 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9610; Control vs. AT-7519, p = 0.0015; Control vs. BMS-345541, p = 0.9888; Control vs. CGP-60474, p = 0.9994; Control vs. ER-27319, p < 0.0001; Control vs. <t>JNJ-7706621,</t> p < 0.0001; Control vs. Alvocidib, p = 0.0170; Control vs. Daunorubicin, p = 0.0004; Control vs. Isomerazin, p < 0.0001; Control vs. Pirarubicin, p < 0.0001. ( F ) Relative mRNA expression levels of Fabp4 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9974; Control vs. AT-7519, p = 0.0017; Control vs. BMS-345541, p = 0.9975; Control vs. CGP-60474, p = 0.0002; Control vs. ER-27319, p = 0.0005; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0032; Control vs. Daunorubicin, p < 0.0001; Control vs. Isomerazin, p = 0.9995; Control vs. Pirarubicin, p < 0.0001. n presents biological replicates. Data are presented as mean ± SEM. Statistical test: one-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical significance is indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns indicates no significant difference. .
Tr0686105, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tr0686105/product/MedChemExpress
Average 93 stars, based on 1 article reviews
tr0686105 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
jnj 7706621  (Selleck Chemicals)
93
Selleck Chemicals jnj 7706621
( A ) Workflow diagram illustrating the process of obtaining thermogenic gene expression profiles associated with browning promotion from RNA-seq data in the GEO database, followed by the use of the CMap database to screen for small molecule compounds that promote browning. ( B ) Heatmap of the top 100 upregulated genes from four RNA-seq datasets. The remaining 100 genes are listed in Table . ( C ) Venn diagram of the four small molecule compound sets identified. ( D ) Representative immunoblot of Ucp1 protein in primary inguinal adipocytes treated with ten candidate small molecule compounds. Rosiglitazone is used as a positive control for adipose browning promotion. ( E ) Relative mRNA expression levels of Ucp1 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9610; Control vs. AT-7519, p = 0.0015; Control vs. BMS-345541, p = 0.9888; Control vs. CGP-60474, p = 0.9994; Control vs. ER-27319, p < 0.0001; Control vs. <t>JNJ-7706621,</t> p < 0.0001; Control vs. Alvocidib, p = 0.0170; Control vs. Daunorubicin, p = 0.0004; Control vs. Isomerazin, p < 0.0001; Control vs. Pirarubicin, p < 0.0001. ( F ) Relative mRNA expression levels of Fabp4 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9974; Control vs. AT-7519, p = 0.0017; Control vs. BMS-345541, p = 0.9975; Control vs. CGP-60474, p = 0.0002; Control vs. ER-27319, p = 0.0005; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0032; Control vs. Daunorubicin, p < 0.0001; Control vs. Isomerazin, p = 0.9995; Control vs. Pirarubicin, p < 0.0001. n presents biological replicates. Data are presented as mean ± SEM. Statistical test: one-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical significance is indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns indicates no significant difference. .
Jnj 7706621, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jnj 7706621/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
jnj 7706621 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
jnj-7706621  (Johnson & Johnson)
90
Johnson & Johnson jnj-7706621
( A ) Workflow diagram illustrating the process of obtaining thermogenic gene expression profiles associated with browning promotion from RNA-seq data in the GEO database, followed by the use of the CMap database to screen for small molecule compounds that promote browning. ( B ) Heatmap of the top 100 upregulated genes from four RNA-seq datasets. The remaining 100 genes are listed in Table . ( C ) Venn diagram of the four small molecule compound sets identified. ( D ) Representative immunoblot of Ucp1 protein in primary inguinal adipocytes treated with ten candidate small molecule compounds. Rosiglitazone is used as a positive control for adipose browning promotion. ( E ) Relative mRNA expression levels of Ucp1 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9610; Control vs. AT-7519, p = 0.0015; Control vs. BMS-345541, p = 0.9888; Control vs. CGP-60474, p = 0.9994; Control vs. ER-27319, p < 0.0001; Control vs. <t>JNJ-7706621,</t> p < 0.0001; Control vs. Alvocidib, p = 0.0170; Control vs. Daunorubicin, p = 0.0004; Control vs. Isomerazin, p < 0.0001; Control vs. Pirarubicin, p < 0.0001. ( F ) Relative mRNA expression levels of Fabp4 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9974; Control vs. AT-7519, p = 0.0017; Control vs. BMS-345541, p = 0.9975; Control vs. CGP-60474, p = 0.0002; Control vs. ER-27319, p = 0.0005; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0032; Control vs. Daunorubicin, p < 0.0001; Control vs. Isomerazin, p = 0.9995; Control vs. Pirarubicin, p < 0.0001. n presents biological replicates. Data are presented as mean ± SEM. Statistical test: one-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical significance is indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns indicates no significant difference. .
Jnj 7706621, supplied by Johnson & Johnson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jnj-7706621/product/Johnson & Johnson
Average 90 stars, based on 1 article reviews
jnj-7706621 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cdk1 2 inhibitors  (Selleck Chemicals)
93
Selleck Chemicals cdk1 2 inhibitors
( A ) Workflow diagram illustrating the process of obtaining thermogenic gene expression profiles associated with browning promotion from RNA-seq data in the GEO database, followed by the use of the CMap database to screen for small molecule compounds that promote browning. ( B ) Heatmap of the top 100 upregulated genes from four RNA-seq datasets. The remaining 100 genes are listed in Table . ( C ) Venn diagram of the four small molecule compound sets identified. ( D ) Representative immunoblot of Ucp1 protein in primary inguinal adipocytes treated with ten candidate small molecule compounds. Rosiglitazone is used as a positive control for adipose browning promotion. ( E ) Relative mRNA expression levels of Ucp1 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9610; Control vs. AT-7519, p = 0.0015; Control vs. BMS-345541, p = 0.9888; Control vs. CGP-60474, p = 0.9994; Control vs. ER-27319, p < 0.0001; Control vs. <t>JNJ-7706621,</t> p < 0.0001; Control vs. Alvocidib, p = 0.0170; Control vs. Daunorubicin, p = 0.0004; Control vs. Isomerazin, p < 0.0001; Control vs. Pirarubicin, p < 0.0001. ( F ) Relative mRNA expression levels of Fabp4 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9974; Control vs. AT-7519, p = 0.0017; Control vs. BMS-345541, p = 0.9975; Control vs. CGP-60474, p = 0.0002; Control vs. ER-27319, p = 0.0005; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0032; Control vs. Daunorubicin, p < 0.0001; Control vs. Isomerazin, p = 0.9995; Control vs. Pirarubicin, p < 0.0001. n presents biological replicates. Data are presented as mean ± SEM. Statistical test: one-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical significance is indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns indicates no significant difference. .
Cdk1 2 Inhibitors, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk1 2 inhibitors/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
cdk1 2 inhibitors - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
jnj 7706621  (Danaher Inc)
86
Danaher Inc jnj 7706621
( A ) Workflow diagram illustrating the process of obtaining thermogenic gene expression profiles associated with browning promotion from RNA-seq data in the GEO database, followed by the use of the CMap database to screen for small molecule compounds that promote browning. ( B ) Heatmap of the top 100 upregulated genes from four RNA-seq datasets. The remaining 100 genes are listed in Table . ( C ) Venn diagram of the four small molecule compound sets identified. ( D ) Representative immunoblot of Ucp1 protein in primary inguinal adipocytes treated with ten candidate small molecule compounds. Rosiglitazone is used as a positive control for adipose browning promotion. ( E ) Relative mRNA expression levels of Ucp1 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9610; Control vs. AT-7519, p = 0.0015; Control vs. BMS-345541, p = 0.9888; Control vs. CGP-60474, p = 0.9994; Control vs. ER-27319, p < 0.0001; Control vs. <t>JNJ-7706621,</t> p < 0.0001; Control vs. Alvocidib, p = 0.0170; Control vs. Daunorubicin, p = 0.0004; Control vs. Isomerazin, p < 0.0001; Control vs. Pirarubicin, p < 0.0001. ( F ) Relative mRNA expression levels of Fabp4 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9974; Control vs. AT-7519, p = 0.0017; Control vs. BMS-345541, p = 0.9975; Control vs. CGP-60474, p = 0.0002; Control vs. ER-27319, p = 0.0005; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0032; Control vs. Daunorubicin, p < 0.0001; Control vs. Isomerazin, p = 0.9995; Control vs. Pirarubicin, p < 0.0001. n presents biological replicates. Data are presented as mean ± SEM. Statistical test: one-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical significance is indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns indicates no significant difference. .
Jnj 7706621, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jnj 7706621/product/Danaher Inc
Average 86 stars, based on 1 article reviews
jnj 7706621 - by Bioz Stars, 2026-02
86/100 stars
  Buy from Supplier

Image Search Results


( A ) Workflow diagram illustrating the process of obtaining thermogenic gene expression profiles associated with browning promotion from RNA-seq data in the GEO database, followed by the use of the CMap database to screen for small molecule compounds that promote browning. ( B ) Heatmap of the top 100 upregulated genes from four RNA-seq datasets. The remaining 100 genes are listed in Table . ( C ) Venn diagram of the four small molecule compound sets identified. ( D ) Representative immunoblot of Ucp1 protein in primary inguinal adipocytes treated with ten candidate small molecule compounds. Rosiglitazone is used as a positive control for adipose browning promotion. ( E ) Relative mRNA expression levels of Ucp1 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9610; Control vs. AT-7519, p = 0.0015; Control vs. BMS-345541, p = 0.9888; Control vs. CGP-60474, p = 0.9994; Control vs. ER-27319, p < 0.0001; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0170; Control vs. Daunorubicin, p = 0.0004; Control vs. Isomerazin, p < 0.0001; Control vs. Pirarubicin, p < 0.0001. ( F ) Relative mRNA expression levels of Fabp4 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9974; Control vs. AT-7519, p = 0.0017; Control vs. BMS-345541, p = 0.9975; Control vs. CGP-60474, p = 0.0002; Control vs. ER-27319, p = 0.0005; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0032; Control vs. Daunorubicin, p < 0.0001; Control vs. Isomerazin, p = 0.9995; Control vs. Pirarubicin, p < 0.0001. n presents biological replicates. Data are presented as mean ± SEM. Statistical test: one-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical significance is indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns indicates no significant difference. .

Journal: EMBO Molecular Medicine

Article Title: Isomeranzin activates Gnas-AMPK signaling to drive white adipose browning and curb obesity in mice

doi: 10.1038/s44321-025-00335-y

Figure Lengend Snippet: ( A ) Workflow diagram illustrating the process of obtaining thermogenic gene expression profiles associated with browning promotion from RNA-seq data in the GEO database, followed by the use of the CMap database to screen for small molecule compounds that promote browning. ( B ) Heatmap of the top 100 upregulated genes from four RNA-seq datasets. The remaining 100 genes are listed in Table . ( C ) Venn diagram of the four small molecule compound sets identified. ( D ) Representative immunoblot of Ucp1 protein in primary inguinal adipocytes treated with ten candidate small molecule compounds. Rosiglitazone is used as a positive control for adipose browning promotion. ( E ) Relative mRNA expression levels of Ucp1 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9610; Control vs. AT-7519, p = 0.0015; Control vs. BMS-345541, p = 0.9888; Control vs. CGP-60474, p = 0.9994; Control vs. ER-27319, p < 0.0001; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0170; Control vs. Daunorubicin, p = 0.0004; Control vs. Isomerazin, p < 0.0001; Control vs. Pirarubicin, p < 0.0001. ( F ) Relative mRNA expression levels of Fabp4 in primary inguinal adipocytes treated with ten candidate small molecule compounds ( n = 3). Control vs. AS-601245, p = 0.9974; Control vs. AT-7519, p = 0.0017; Control vs. BMS-345541, p = 0.9975; Control vs. CGP-60474, p = 0.0002; Control vs. ER-27319, p = 0.0005; Control vs. JNJ-7706621, p < 0.0001; Control vs. Alvocidib, p = 0.0032; Control vs. Daunorubicin, p < 0.0001; Control vs. Isomerazin, p = 0.9995; Control vs. Pirarubicin, p < 0.0001. n presents biological replicates. Data are presented as mean ± SEM. Statistical test: one-way ANOVA followed by Dunnett’s multiple comparisons test. Statistical significance is indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns indicates no significant difference. .

Article Snippet: JNJ-7706621 , MedChemExpress , HY-10329.

Techniques: Gene Expression, RNA Sequencing, Western Blot, Positive Control, Expressing, Control